Ronsheim Matthew 4
4 · Entasis Therapeutics Holdings Inc. · Filed Feb 15, 2022
Insider Transaction Report
Form 4
Ronsheim Matthew
See Remarks
Transactions
- Disposition to Issuer
Employee Stock Option (Right to Buy)
2021-07-16−40,000→ 0 totalExercise: $5.12Exp: 2029-09-16→ Common Stock (40,000 underlying) - Award
Employee Stock Option (Right to Buy)
2021-07-16+33,333→ 33,333 totalExercise: $2.44Exp: 2031-07-15→ Common Stock (33,333 underlying)
Footnotes (3)
- [F1]The option provided for vesting as follows: Twenty-five percent (25%) of the option award will vest on September 17, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
- [F2]On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 40,000 shares of issuer's common stock granted to the Reporting Person on September 17, 2019. In exchange, the Reporting Person received a replacement option for 33,333 shares of issuer's common stock, having an exercise price of $2.44 per share.
- [F3]Sixty-nine percent (69%) of this award will vest on July 16, 2022, and one-fifteenth of the remaining shares subject to the option will vest monthly following July 16, 2022, subject to the Reporting Person's continuing to provide service through each such date.